• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

ADA: Metabolic Syndrome Helps Predict Mortality Risk

Article

CHICAGO -- Metabolic syndrome and its components helped predict mortality for diabetic and non-diabetic patients alike, independently of Framingham cardiovascular risk, researchers found.

CHICAGO, June 26 -- Metabolic syndrome and its components helped predict mortality for diabetic and non-diabetic patients alike, independently of Framingham cardiovascular risk, researchers found.

In a large study of patients at a preventive cardiology clinic, metabolic syndrome was associated with 53% higher mortality risk than seen among patients who did not have diabetes or metabolic syndrome, said Krupa B. Doshi, M.D., of the Cleveland Clinic, and colleagues.

Fasting plasma glucose and waist circumference-components of metabolic syndrome-were significant predictors of mortality risk in an analysis that adjusted for Framingham score and other factors (P

Mortality rates were highest for patients with diabetes (hazard ratio 2.97, 95% confidence interval 2.33 to 3.79, P

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Preventive cardiology: primary care clinicians greatest patient exposure to help advance care.
ASCVD treatment, preventive cardiology, Seth Baum, MD
Related Content
Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial

Oral PCSK9 Inhibitor Enlicitide Meets All End Points in Phase 3 Hypercholesterolemia Trial

Patient Care Editorial Staff
September 2nd 2025
Article

At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.

Site Logo

Women and Heart Disease: Incidence, Prevalence, Progress, and the Future

C Noel Bairey Merz, MD;Payal Kohli, MD
April 6th 2013
Podcast

Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women

RDX-002 Hits Primary and Secondary Endpoints for Post-GLP-1 Weight Management / image credit ©missbobbit/stock.adobe.com

RDX-002 Hits Primary and Secondary End Points for Post–GLP-1 Weight Management

Grace Halsey
August 14th 2025
Article

RDX-002, an investigational, first-in-class therapeutic, significantly reduced weight regain after cessation of antiobesity treatment with semaglutide and tirzepatide.

Site Logo

The Mediterranean Diet in Primary Cardiovascular Prevention

Payal Kohli, MD;Michael J. Blaha, MD, MPH
March 20th 2013
Podcast

Patients who consumed a Mediterranean-style diet had a 30% reduction in major cardiovascular events compared with patients who ate a diet low in saturated fat.

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection / image courtesy of University of Oxford

Smart Ring Outperforms Apple Watch for Atrial Fibrillation Detection

Grace Halsey
April 21st 2025
Article

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

First Rivaroxaban Generics (2.5 mg) Get FDA Approval / image credit ©samunella/stock.adobe.com

First Rivaroxaban Generics (2.5 mg) Get FDA Approval

Grace Halsey
March 5th 2025
Article

The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.

© 2025 MJH Life Sciences

All rights reserved.